The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
Subscribe To Our Newsletter & Stay Updated
